UMI3 gives exclusive licence for SenTraGor to Arriani Pharmaceuticals


The University of Manchester’s technology transfer company, UMI3, has entered an exclusive licence deal with Arriani Pharmaceuticals for a research tool that helps clarify the role of senescent cells in several age-related diseases, including cancer.

Known as SenTraGor, the universally applicable research tool, developed by professors Vassilis Gorgoulis and Paul Townsend, will facilitate the better detection of senescence or the aging of cells.

According to Townsend, the detection of aging cells has been difficult and infeasible to date in the most widespread biological material.

Gorgoulis said: “SenTraGor revolutionises the field of cellular aging and opens the door to a better understanding and treatment of various disorders.

"SenTraGor revolutionises the field of cellular aging and opens the door to a better understanding and treatment of various disorders."

“Many cancer types, degenerative diseases, even infertility, are thought to be senescence-related and our method introduces a powerful weapon in the medical armoury against these conditions.”

Under the deal, Arriani Pharmaceuticals will be responsible for providing SenTraGor to different research institutions, diagnostic laboratories, clinics and companies that seek new therapies and offer a wide range of well-being services.

Arriani Pharmaceuticals president and founder Harry Lambridis said: “We are proud to offer to the international scientific community the valuable outcome of the research conducted by professors Vassilis Gorgoulis and Paul Townsend that will revolutionalise the detection of senescent cells.

“We strongly believe that SenTraGor will greatly contribute to the understanding of age-related biological processes and to this end we will work closely with the professors to enlarge the applications of SenTraGor, even beyond this field.”


Image: UMI3’s SenTraGor. Photo: courtesy of The University of Manchester Intellectual Property.